Chengdu Shengnuo Biotechnology's (SHA:688117) unit, Chengdu Shengnuo Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for its exenatide injection, according to a Shanghai bourse filing on Tuesday.
The drug is used to improve glycemic control in patients with type 2 diabetes, particularly in cases where blood glucose remains inadequately controlled with monotherapy using metformin, sulfonylureas, or a combination of metformin and sulfonylureas, the pharmaceutical company said.
The company's shares closed less than 5% higher.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments